Background & Aims: Non-celiac gluten sensitivity is characterized by symptom 77 improvement after gluten withdrawal in absence of celiac disease. The mechanisms of non-78 celiac gluten sensitivity are unclear, and there are no biomarkers for this disorder. Foods with 79 gluten often contain fructans, a type of fermentable oligo-, di-, monosaccharides and polyols. 80
We aimed to investigate the effect of gluten and fructans separately in individuals with self-81 reported gluten sensitivity. 82
Methods:
We performed a double-blind crossover challenge of 59 individuals on a self-83 instituted gluten-free diet, for whom celiac disease had been excluded. The study was 84 performed at Oslo University Hospital in Norway from October 2014 through May 2016. 85
Participants were randomly assigned to groups placed on diets containing gluten (5.7 g), 86
fructans (2.1 g), or placebo, concealed in muesli bars, for 7 days. Following a minimum 7-day 87 washout period (until the symptoms induced by the previous challenge were resolved), 88 participants crossed over into a different group, until they completed all 3 challenges (gluten, 89 fructan, and placebo). Symptoms were measured by gastrointestinal symptom rating scale 90 irritable bowel syndrome (GSRS-IBS) version. A linear mixed model for analysis was used. 91
Results: Overall GSRS-IBS scores differed significantly during gluten, fructan, and placebo 92 challenges; mean values were 33.1±13.3, 38.6±12.3, and 34.3±13.9, respectively (P = .04). 93
Mean scores for GSRS bloating were 9.3±3.5, 11.6±3.5, and 10.1±3.7, respectively, during 94 the gluten, fructan, and placebo challenges (P = .004). The overall GSRS-IBS score for 95 participants consuming fructans was significantly higher than for participants consuming 96 gluten (P = .049), as was the GSRS bloating score (P = .003). Thirteen participants had the 97 highest overall GSRS-IBS score after consuming gluten, 24 had the highest score after 98 consuming fructan, and 22 had the highest score after consuming placebo. There was no 99 difference in GSRS-IBS scores between gluten and placebo groups. The interest in gluten-free diet and self-diagnosis of gluten sensitivity has risen worldwide. 1 109
International consensus statements have defined non-celiac gluten sensitivity (NCGS) as a 110 condition in which ingestion of gluten induces gastrointestinal and extra-intestinal symptoms 111 in absence of celiac disease or wheat allergy. 2, 3 112
The condition represents a diagnostic problem as there are no reliable biomarkers and the 113 clinical picture overlaps with irritable bowel syndrome (IBS). 2 A standardized double-blind 114 placebo-controlled food challenge (DBPCFC) has been proposed as a diagnostic tool to 115 confirm the NCGS. 4 However, the clinical value of DBPCFC is questionable. 2, 5, 6 116 The pathogenesis of NCGS is incompletely understood. Negative serology for specific 117 antibodies and lack of association with HLA DQ2/DQ8 suggest a limited involvement of 118 adaptive immune mechanisms. 7 A higher expression of toll-like receptors in intestinal 119 mucosa of NCGS patients compared to celiac disease patients, indicate a stronger role of 120 innate immune mechanisms in NCGS. 7 Studies have shown increased intraepithelial 121 lymphocytes (IEL), changes in intestinal permeability and cytokine response after challenge, 122 but all findings have been considered unreliable as diagnostic biomarkers. 7, 8 Thus, the 123 diagnosis is predominantly based on exclusions and self-statements. 124
Gluten-containing cereals can induce symptoms, but the culprit molecule is unknown. Wheat 125 contains more than one potential symptom inducer such as gluten, fructans (an 126 oligosaccharide of the FODMAPs) and soluble proteins. 8, 9 Gluten has shown to induce 127 symptoms in some studies, 10, 11 but not in placebo-controlled cross-over studies. [12] [13] [14] [15] Further, 128 α-amylase trypsin inhibitors (ATI) have been proposed as possible symptom triggers 129 although there are no supporting data in humans. 16 FODMAP restriction in study diets has 130 resulted in symptom reduction, 12, 17 but FODMAPs alone have not been re-introduced in any Eligible participants were adults aged 18-80 years who self-instituted in gluten-free diet. They 138 were required strict diet adherence for at least six months. They were asked on a re-call 139 Highgate Hill, QLD, Australia). FODMAPs were quantified via laboratory analysis using 161 HPLC, UPLC and enzymatic assays as described previously. Gluten-free diet adherence 162 M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT 9 was assessed at baseline by trained dietitians, evaluated by a standardized, locally-163 developed questionnaire and confirmed by the seven-day food record. Adherence during the 164 study was not re-evaluated, but the participants were asked to keep their diet consistent with 165 the baseline diet throughout the study. 166
167
Participants were randomized to one of three seven-day challenges (gluten, fructan or 168 placebo), followed by a minimum of one-week washout period ( Supplementary Figure 1) . 169
The washout period was extended until the symptoms induced by the previous challenge 170 were resolved before starting the next challenge. This was ensured by a study team member 171 who evaluated the washout symptoms recordings against baseline symptom level and 172 decided prolonging of the washout period when needed. 173
174
The challenge vehicle was a 50 g, 220 kcal low-FODMAP gluten-free muesli bar developed 175 and produced by the Monash University, Melbourne ( Supplementary Table 1 -2), eaten once 176 daily. Fructo-oligosaccharides (Orafti® Oligofructose, Beneo, Tienen, Belgium) 2.1 g was 177 added to the fructan bar, and gluten 5.7 g was added to the gluten bar, both of which 178 mimicked the amount in four slices of sandwich wheat bread. The gluten used was 179 commercially available, carbohydrate-depleted wheat gluten (Vital Wheat Gluten, Manildra 180
Group, Gladesville, New South Wales, Australia). The muesli bars had similar appearance 181 and taste as 12 healthy adults were not able to differentiate their content in a pre-test (data 182 not shown). 183
184
To detect and quantify prolamins in the gluten-containing muesli bar, they were analyzed by 185 R5-ELISA Ridascreen ® Gliadin (R-Biopharm AG, Darmstadt, Germany) and by mass-186 spectrometry (nano-LC-MS/MS)(data not shown). 19 Gluten-derived peptides including the 
Sample size 210
Sample size calculation was based on paired t-test of differences between two challenges 211 within the same subject. The total level of significance was set to .05 (two-sided), and we 212 used .02 for the pairwise comparisons (.05/3, Bonferroni multiple comparison correction). A 213 previous study found a GSRS-IBS mean difference of 1.5 units and a standard deviation 214 (SD) of 3.2. 25 With 80% power and anticipated drop-out of 30%, 66 participants were 215 required to detect such a difference. 216
Randomization and blinding 218
The study statistician with no clinical involvement in the study prepared the randomization 219 sequence for the three challenges to be given in three periods of six sequences (ABC, ACB, 220 BAC, BCA, CAB and CBA) by using a web-based service (http://randomization.com/, second 221 generator, balanced permutations, accessed September 26, 2014). Block size was equal to 222 trial size. 26 All participants and study team members were blinded throughout the study. The 223 allocation concealment was carried out according to a procedure approved by the 224 Department of Clinical Research Support. Seven muesli bars of each type were packed into 225 three separate envelops marked with individual codes 1-66 and week (period) numbers 1-3 226 according to the randomization sequence. Sealed envelopes were handed out to the 227 participants one week at a time. The participants recorded eaten muesli bars in a diary and 228 returned uneaten bars. Un-blinding was done after the statistical analyses of primary and 229 secondary outcomes. 230 231
Statistical methods 232
Descriptive results are presented as frequency (%), mean (SD) and median (interquartile 233 range, IQR). Differences between the challenge responses were analyzed by linear mixed 234 model. Participants were modelled as random with a random intercept at participant level. 235
Challenge, period and sequence were modelled as fixed effects. Since we found no 236 significant effect of sequence for any of the outcome variables, sequence was removed from 237 the models. Baseline values were included as covariates. Day was included in the analysis of 238
VAS symptom scores. We tested for interaction between challenge and period, and when 239 significant, effect of challenge was analyzed by a linear mixed model within each period. 240
Differences between baseline and washout were analyzed with one way analysis of variance 241 (ANOVA), and differences between participants with and without thyroid disease were appropriate. All analyses were carried out using IBM SPSS, version 24.0 (SPSS Inc, Chicago 246 IL) and a P-value < .05 was considered statistically significant. 247
248
Ethics and approvals 249
The study was conducted in accordance to the Helsinki Declaration. Written informed 250 consent was obtained from all participants, and the study was approved by the Regional 251 Of 232 participants assessed, 68 were eligible (Figure 1) . Reasons for the 111 participants 262 not meeting the inclusion criteria were: celiac disease not properly excluded (n=61), long 263 travel distance (n=20), not following a gluten-free diet (n=21), symptomatic on gluten-free 264 diet (n=4), celiac disease (2) or already investigated for NCGS (3). Two participants were in 265 excess of the predefined 66 participants needed and excluded from the final analysis to 266 avoid violation of the randomization protocol and the size of the sequences. These two 267 completed the full protocol fully aware from the start that we could not include them in the 268 statistical analysis. Three participants were excluded due to protocol violations. One had a 269 biopsy compatible with active celiac disease at the baseline gastroscopy despite a gluten-270 free diet and previous negative biopsy on a gluten-containing diet and was later given a 271 celiac disease diagnosis. Two were positive for the celiac disease-associated HLA types 272 (HLA-DQ2 and -DQ8), were on a strict gluten-free diet, but did not have celiac disease ruled 273 out. The remaining 59 participants completed all three challenges and were included in the 274 statistical analysis. Of these, gluten and fructan challenges were prematurely ceased by 275 seven participants each, after 5-6 days. Placebo challenge was prematurely ceased by four 276 participants, after 2-6 days. Cessation was due to omission or unbearable symptoms and did 277 not exclude the participant from analysis. No participants experienced severe adverse effects 278 of the challenges. During the challenges all participants self-reported strict adherence to 279 gluten-free diet, and 98% of the muesli bars were consumed. 280 281
Baseline data 282
Baseline characteristics of the study sample are presented in Table 1 . According to recall 283 information the last three months, 18 participants fulfilled the Rome III criteria for IBS, despite 284
reporting symptom relief on gluten-free diet. IBS was not an exclusion criterion. Two 285 participants had IgG-deamidated gliadin peptide above the cut-off (20 U/ml), 22 and 38 U/ml, 286
respectively. They carried the genotype HLA DQ2.5 or DQ8, but had negative duodenal 287 biopsy while on gluten-containing diet. Five participants had changes equivalent to Marsh-288
Oberhuber type 1 in the baseline duodenal biopsy. 27 Two of these had celiac disease ruled 289 out by negative HLA DQ2/DQ8 and three had previous negative duodenal biopsy. 290
Self-reported thyroid disease was present in 27 % of the participants, reflected by 291 significantly different thyroid stimulating hormone values in this group compared to the rest 292 (mean (SD) 0.5 (0.8) vs 1.5 (0.9) IU/L, respectively; P < .001) but free T 4 levels did not differ 293 significantly (16.7 (4.1) vs 15.0 (2.3) pmol/L, respectively P = .13). However, there were no 294 significant differences in gastrointestinal or extra-intestinal baseline symptoms between 295 participants with and without thyroid disease, except that SF-36 general health scale was 296 lower in participants with thyroid disease than in those without thyroid disease, 37 (22) vs 65 297 (26), respectively (P = .05). 298
Participants adhered strictly to the gluten-free diet at baseline, except one individual who 299 reported one accidental transgression by intake of rye crisp bread and one individual who ate 300 barley porridge on two occasions, both during the seven-day baseline food record. They 301 were otherwise diet-adherent. Based on the seven-day food record the mean (SD) individual 302 fructan intake was 2.5 g (2.1) per day. 303 304
Primary outcome 305
There was a significant difference in mean overall GSRS-IBS across gluten, fructan and 306 placebo challenges, mean (SD) scores were 33.1 (13.3), 38.6 (12.3) and 34.3 (13.9), 307 respectively (P = .04, Figure 2 ). Corrected for multiple comparisons the overall GSRS-IBS 308 was borderline significant for fructan versus gluten (P < .049). No significant differences were 309 found for fructan versus placebo (P = .19) and gluten versus placebo (P = .99). 310
311
There was also a significant difference in GSRS-IBS bloating across gluten, fructan and 312 placebo challenge, where mean (SD) scores were 9.3 (3.5), 11.6 (3.5) and 10.1 (3.7), 313 respectively (P = .004). Corrected for multiple comparisons the GSRS-IBS bloating was 314 M A N U S C R I P T
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15 significantly different for fructan versus gluten (P = .003), but not for fructan vs placebo (P = 315
.07) or for gluten versus placebo (P = .84). The fructan challenge induced highest score in 316 the GSRS dimensions pain, diarrhea and satiety, but the differences were not significant (.07 317 ≤ P ≤ .15). No significant difference was found for the dimension of constipation (P = .93, 318 Figure 2 ). There were no significant effects of period (.23 ≤ P ≤ .81), and no significant 319 interactions between challenge and period (.13 ≤ P ≤ .66). However, when we studied the 320 effect of challenge within each period, mean overall GSRS-IBS was consistently highest after 321 the fructan challenge in all three periods, significantly so in period 2 (P = .03, Supplementary 322 Figure 2 ). In the overall GSRS-IBS in period 2, there was significant difference for fructan 323 versus placebo (P = .03), while no significant differences were found for gluten versus fructan 324 (P = .10) or gluten versus placebo (P = .78). 325
The difference from placebo was significant for the fructan challenge, but not for the gluten 326 challenge, P = .04 and P = .55, respectively (Figure 3) . The difference fructan minus placebo 327 was significantly higher than the difference gluten minus placebo. This difference was found 328 also for the GSRS-IBS dimensions bloating (P = .002) and diarrhea (P = .04, data not 329 shown). 330
We did a post-hoc observation of individual courses according to the overall GSRS-IBS 331 stratified by those scoring highest and lowest on gluten, and those who scored highest after 332 fructan and placebo challenge (Figure 4 ). Thirteen participants scored highest after gluten 333 challenge. Four of these had a difference in score between gluten and placebo above 30%. 334
According to a previously suggested diagnostic tool these four would have been defined as 335 gluten-sensitive. 4 Lowest score after gluten was found in 27 participants. Highest score after 336 fructan and placebo challenge was found in 24 and 22 participants, respectively. 337
Subject-related factors were added as fixed factors in the linear mixed model, and no effect 338 was found of age, gender, duration of gluten-free diet, BMI, HLA-DQ status, thyroid disease 339 or IBS (.17 ≤ P ≤ .78). The mean (SD) duration of the first and second washout periods were 340 9 (7.2) days and 13 (7.2) days, respectively. There was no significant difference between 341 M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT baseline and washout symptom scores for overall GSRS-IBS (P = .76) or GSRS-IBS 342 dimensions (.38 ≤ P ≤ .96). 343
Secondary outcome 344
Overall gastrointestinal symptoms scored by VAS were consistently higher after fructan 345 challenge than after gluten and placebo challenge from day one to day seven ( Figure 5A) . 346
However, there was a significant interaction between challenge, period and day (P interaction = 347
.01), thus we present results for overall symptoms stratified by period ( Figure 5B-D) . 348
In period one, there was a significant difference across the gluten, fructan and placebo 349 challenge (P = .04), but no pairwise comparisons were significantly different (.52 ≤ P ≤ 1.00). 350
In period two, the fructan scores were highest and placebo scores lowest all days, and, at 351 day 3, 6 and 7, the differences across the three challenges were significant (P < .008 for all 352 comparisons). On these days the fructan scores were significantly higher than the placebo 353 scores (P < .006). ANOVA also indicated differences between fructan and placebo at day 2 354 and 4 (P = .09 and P = .07, respectively). No other comparisons in period two were 355 significantly different (.07 ≤ P ≤ .99). The fructan scores seemed to increase more than 356 gluten and placebo scores from day one to day seven. However, no challenge effect was 357 found by linear mixed model (P = .48, Figure 5C ). In period three, there was significant 358 interaction between challenge and day illustrated by the crossing lines in Figure 5D (P interaction 359 = .02). VAS bloating scores were also consistently higher after fructan challenge than after 360 gluten and placebo challenge from day one to day seven (data not shown). However, there 361 was a significant interaction between challenge, period and day in the VAS measurements of 362 bloating (P interaction = .02). There were no interactions for the other VAS measurements (.06 ≤ 363 P interacton ≤ .84). There were no significant challenge by period, challenge by day or period by 364 day interactions for pain, wind and stool dissatisfaction (.06 ≤ P interaction ≤ .88), but for nausea 365 there was a significant challenge by period interaction (P interacton ≤ .02). There were no 366 significant effects of challenge on abdominal pain, wind and stool dissatisfaction by VAS (.23 367 ≤ P ≤ .88, data not shown). In regards to other secondary outcomes, there was a significant difference in SF-36 vitality 370 scale scores across gluten, fructan and placebo challenge, and lowest vitality was found after 371 fructan challenge, mean (SD) 44.3 (25.2), 38.2 (23.4) and 44.4 (24.3), respectively (P = .04, 372
Supplementary Table 3 ). The GBB dimension, weakness, was significantly different across 373 gluten, fructan and placebo challenge, and highest weakness was found after fructan 374 challenge, 32.8 (30.0), 42.5 (26.6) and 33.5 (29.7), respectively (P = .02). In the pairwise 375 comparisons, the vitality score was significantly lower and weakness significantly higher after 376 fructan challenge than after gluten challenge (P = .04 and P = .02, respectively). No 377 significant differences were found for fructan versus placebo or gluten versus placebo for 378 these two variables (.11 ≤ P ≤ .99). No significant differences were found for the other SF-36 379 scales and measures for fatigue, or for other extra-intestinal symptoms (.10 ≤ P ≤ .96, 380 Supplementary Table 3) . This randomized double-blind placebo controlled cross-over study aimed to investigate the 384 effects of gluten (without fructan) and fructan (without gluten) on gastrointestinal symptoms in 385 individuals with self-reported gluten-sensitivity. No significant effect of gluten was found as 386 compared to placebo and fructan. In contrast, a small daily dose of 2.1 g of fructans induced 387 greater symptoms on multiple criteria including the overall GSRS-IBS, after a seven-day 388 challenge. On group level, the difference from placebo was significantly higher after fructan 389 challenge than after gluten challenge. Thirteen participants had their highest symptom score 390 after gluten, while 27 had their lowest score after gluten challenge. Fructan and placebo 391 challenge induced highest score in 24 and 22 participants, respectively. 392
393
We deliberately challenged our participants with moderate doses of gluten and low doses of 394 fructans to resemble the clinical situation as closely as possible. The baked muesli bars 395 mimicked gluten-containing food and enabled successful blinding. To date, no studies have 396 used this challenge vehicle. As an evidence of an active immunogenic gluten-component in 397 the musli bars, participants with biopsy-proven celiac disease who were challenged with the 398 gluten bars for 14-days in a related study developed significant increase in IEL-count and 399 significant reduction in villous height to crypt depth ratio in duodenal biopsies by the end of 400 challenge. 28 Further, analysis of the bars confirmed that they specifically contained the food 401 components of interest without other potential culprit food components. 402
With such confidence in the challenge bars, the lack of gluten-specific responses according 403 to both GSRS-IBS and VAS supports the assumption that gluten plays a less prominent role 404 in symptom generation than initially anticipated. 29 Additional support is that only 13 of 59 405 participants had their highest symptom score after gluten challenge and 27 had the lowest 406 score after gluten challenge. The moderate dose of 5.7 g gluten is believed to be adequate 407 since previous studies have been able to demonstrate symptom responses on equivalent 408 M A N U S C R I P T
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and lower amounts of gluten. 13, 14 The re-challenge methodology, however, cannot exclude 409 gluten sensitivity in some individuals due to possibly stronger placebo response. 410
The effect of fructans on overall gastrointestinal symptoms by GSRS-IBS was found both on 411 a group level and in individuals. In the current study, the fructan challenge almost doubled 412 their habitual daily fructan exposure. The effect of FODMAPs on symptoms in patients with 413 IBS is dose-dependent and the doubling of amount received is sufficient to cause 414 symptoms. 30 By comparison, in a recent pilot study, 21 healthy adults did not experience 415 gastrointestinal response to 5 g of fructo-oligosaccharides. 31 Hence, it is likely that the 416 fructan effect in 24 of 59 participants who had their highest symptom score after fructan 417 challenge represents a causal relationship. 418
However, symptoms may depend on combined exposure to gluten and fructans with 419 synergistic actions. The combination reflects the clinical scenario when patients report 420 symptoms after intake of wheat. This combination has not been studied. It is also possible 421 that fructans present naturally in the food matrix behaves differently to supplements of pure 422 fructo-oligosaccharides added to the diet. Further, the fructo-oligosaccharide added in the 423 muesli bars originated from chicory roots and might have different effect from the fructo-424 oligosaccharide in wheat. Other components of wheat, such as the ATIs and the lectin, 425 wheat germ agglutinin, were not considered in the current study apart from not being able to 426 detect the ATIs. 16 In vitro studies have found effect on cell activation of these components, 16, 427 32 but in IBS and NCGS patients the pathogenic role of ATIs and wheat germ agglutinin is 428
unexplored. 429
Although the differences in the symptoms induced across the challenges were small, the 430 fructan effect was distinct and consistent for many symptoms. Bloating is frequently reported 431 by IBS and NCGS patients and was the only GSRS-IBS sub dimension that showed 432 significant response of the fructan challenge. This result is supported by significant 433 improvement of bloating as a response to low FODMAP diet reduction in IBS patients. 17 434 Likewise, the present lack of fructan effect on bowel habits supports the lack of effect on 435 appearances and fecal water content in a feeding intervention. 33 436
The effect of the fructan challenge was not restricted to abdominal symptoms. The SF-36 437 vitality scale was significantly lower and VAS weakness significantly increased as response 438 to the fructan challenge compared to gluten and placebo. Improvement in quality of life in IBS 439 patients has been found as an effect of low FODMAP diet. 34 Whether improvement in vitality 440 and weakness are directly related to fructan exposure or secondary to the higher degree of 441 gastrointestinal symptoms cannot be ascertained. 442
The results of the current study weaken the role of gluten as a symptom inducer in patients 443 A possible role of gluten as symptom inducer in participants with self-reported NCGS has 452 been shown in randomised double-blind placebo-controlled challenge studies. [13] [14] [15] The 453 authors may conclude justly that some participants are gluten-sensitive, but methodological 454 issues make it difficult to rely on the finding as a correct identification of the gluten sensitive 455 individuals. The current findings contrast these previous studies and weaken the role of 456 gluten as symptom trigger in individuals intolerant of wheat, rye or barley. Rather, the results 457 indicate that fructans are more likely the culprits. 30 The finding raises issue regarding the use 458 of the term "NCGS" and its distinction from IBS. This is consistent with studies that report 459 that some IBS patients do benefit from a gluten-free diet. 11, 35 However, the improvement 460 seen with a gluten-free diet may not be caused by removal of the gluten protein per se, but 461 rather the reduction of wheat fructans. 462
Large placebo response as seen in previous studies demonstrates how difficult it is to 463 correctly identify which patients should be gluten-free. [13] [14] [15] Our DBPCFC also resulted in 22 464 M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT 21 of 59 participants with placebo response. It is therefore appropriate to question whether the 465 DBPCFC in clinical practice is a good tool or even necessary to identify these individuals. 466
Re-challenges of participants with gluten-specific score above a cut-off are usually not done, 467
and not suggested as a diagnostic tool. 4 It was done in the study of Biesiekierski et al., but 468 the gluten specificity was lost. 12 469 A common clinical approach when food is suspected to induce symptoms is the elimination 470 of the suspected trigger followed by a clinician-supervised open, systematic re-challenge with 471 symptom monitoring. The method is used for patients on a low FODMAP diet, not for 472 diagnostic purpose, but the approach serves as confirmation of the IBS diagnosis according 473 to the ROME IV criteria. The DBPCFC would not be suitable in a re-challenge of FODMAPs 474 because of the impossibility of blinding. Still, the DBPCFC is currently the preferred method 475 to define food intolerances. It may work for the purpose of proving the existence of a 476 condition, but is less useful as a clinical tool. 5 As long as NCGS is a poorly defined condition 477 with strongly subjective symptoms, standardized open food challenges are meaningful 478 enough for the clinical practice. 5, 36 Followed by long-term monitoring by experienced 479
clinicians, this open-ended perspective could be superior to a conclusive DBPCFC with risk 480 of false negative and false positive results without the possibility to contrast with objective 481
biomarkers. 5 482
The general influence of confounding factors in the present study was reduced by using the 483 randomised crossover design. 37 However, the design is complex and demanding. Therefore, 484 dietary and adherence assessment was done before challenge, and not continued through 485 the challenges. Unobserved dietary changes might have occurred during the study. A fructan 486 restriction could have been done in the run-in period to reduce the heterogeneity of the 487 fructan intake before challenge. However, we abstained from manipulating their normal diet 488 to better represent the clinical setting, an approach also used by Laatikainen et al. 38 The 489 heterogeneity of the participants is a common characteristic of the NCGS population, 39 but 490 must also be considered as possible disturbance in interpretation of the results. We 491 deliberately abstained from manipulating the study sample to make the participants present 492 M A N U S C R I P T
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as close to a clinical setting as possible. However, in regards to gender, thyroid disease, IBS 493 and celiac disease in close family our sample was very much alike the samples described in 494 other challenge and cross-sectional studies. 12, 13, 15, [40] [41] [42] Further, we did not find any effect of 495 any of these factors on the challenge outcome. Regarding adequate exclusion of celiac 496 disease and celiac disease serology, our sample was more homogenous than in previous 497 challenge studies. 12, 13 Recall bias may occur when recording symptoms seven days 498 retrospectively by GSRS-IBS. However, the method is established as a tool to monitor 499 response during gluten challenge in celiac disease and NCGS patients, 25, 43 Further, the daily 500 scored VAS scales that have been used in similar challenge studies 12, 14 confirmed the main 501 findings of GSRS-IBS in the present study. 502
The significant interaction effect between challenge, period and day indicated that the effect 503 of challenge differed between periods and days for overall symptoms by VAS. It is not likely 504 that the period effect was caused by a carry-over effect. Washout and baseline symptom 505 scores were similar, indicating that the washout periods were of adequate length. The period 506 effect is a hurdle of the crossover design 12, 13 and might be a cause of participant expectancy 507 commonly observed in participants with a strong preconception of food intolerances. 37 This 508 expectancy is often highest in the first period. 12, 13 Theoretically, repeated placebo-controlled 509 challenges may be an approach to overcome the period effect. 510
511
In conclusion, the current randomized, double-blind placebo-controlled crossover challenge 512 in participants with self-reported NCGS found no effect of gluten on group level. The study 513
indicates that fructans are more likely to induce symptoms in those reporting sensitivity to 514 wheat, rye and barley. The finding weakens the use of the term "NCGS" and raises doubts 515 about the need for a gluten-free diet in such patients. 
